ArticleMolecular pharmacology2017
Thiosemicarbazones Functioning as Zinc Metallochaperones to Reactivate Mutant p53.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
4.2field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Potential Biological Targets of Anticancer Metal-Based Drug Candidates: A Systematic Review.Drug development research · 2026Pooled it
- Targeting p53 pathways: mechanisms, structures, and advances in therapy.Signal transduction and targeted therapy · 2023Pooled it
- Article
- Review
- p53: from understanding its structure to advances in therapeutic targeting.Signal transduction and targeted therapy · 2026Review
- Functional restoration of conformational (R175H) and contact (R273H) mutant p53 byFrontiers in bioinformatics · 2026Article
- Discovery of Drugs Targeting Mutant p53 and Progress in Nano-Enabled Therapeutic Strategy for p53-Mutated Cancers.Biomolecules · 2025Review
- ComparativeProtein and peptide letters · 2025Article
- TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review).International journal of molecular medicine · 2025Review
- From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy.Biomarker research · 2024Review
- Retinoic acid mitigates the NSC319726-induced spermatogenesis dysfunction through cuproptosis-independent mechanisms.Cell biology and toxicology · 2024Article
- Article
- Review
- The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer.Biomolecules · 2023Review
- Biological investigation ofJournal of enzyme inhibition and medicinal chemistry · 2022Article
- Article
- A role for bioinorganic chemistry in the reactivation of mutant p53 in cancer.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2022Review
- Recent findings on the role of wild-type and mutant p53 in cancer development and therapy.Frontiers in molecular biosciences · 2022Review
- Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting.Biochimica et biophysica acta. Reviews on cancer · 2021Review
- Modulation of Intracellular Copper Levels as the Mechanism of Action of Anticancer Copper Complexes: Clinical Relevance.Biomedicines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Xin YuRutgers Cancer Institute of New Jersey (X.Y., A.T.T., S.Z., Y.L., D.R.C.), Department of Surgery, Rutgers Robert Wood Johnson Medical School (X.Y., A.T.T, Y.L., D.R.C.), Rutgers Translational Sciences, Department of Chemistry and Chemical Biology (S.D.K.), Department of Medicinal Chemistry, Rutgers Ernest Mario School of Pharmacy (J.G., A.F.B., S.D.K.), Rutgers University, New Brunswick, New Jersey; Department of Biochemistry and Molecular Biology, State University of New York (SUNY) Upstate Medical University, Syracuse, New York (A.B., S.N.L.); and Mount Sinai St. Luke's Roosevelt General Surgery Residency Program, New York, New York (A.T.T.).
Adam BlandenRutgers Cancer Institute of New Jersey (X.Y., A.T.T., S.Z., Y.L., D.R.C.), Department of Surgery, Rutgers Robert Wood Johnson Medical School (X.Y., A.T.T, Y.L., D.R.C.), Rutgers Translational Sciences, Department of Chemistry and Chemical Biology (S.D.K.), Department of Medicinal Chemistry, Rutgers Ernest Mario School of Pharmacy (J.G., A.F.B., S.D.K.), Rutgers University, New Brunswick, New Jersey; Department of Biochemistry and Molecular Biology, State University of New York (SUNY) Upstate Medical University, Syracuse, New York (A.B., S.N.L.); and Mount Sinai St. Luke's Roosevelt General Surgery Residency Program, New York, New York (A.T.T.).
Ashley T TsangRutgers Cancer Institute of New Jersey (X.Y., A.T.T., S.Z., Y.L., D.R.C.), Department of Surgery, Rutgers Robert Wood Johnson Medical School (X.Y., A.T.T, Y.L., D.R.C.), Rutgers Translational Sciences, Department of Chemistry and Chemical Biology (S.D.K.), Department of Medicinal Chemistry, Rutgers Ernest Mario School of Pharmacy (J.G., A.F.B., S.D.K.), Rutgers University, New Brunswick, New Jersey; Department of Biochemistry and Molecular Biology, State University of New York (SUNY) Upstate Medical University, Syracuse, New York (A.B., S.N.L.); and Mount Sinai St. Luke's Roosevelt General Surgery Residency Program, New York, New York (A.T.T.).
Saif ZamanRutgers Cancer Institute of New Jersey (X.Y., A.T.T., S.Z., Y.L., D.R.C.), Department of Surgery, Rutgers Robert Wood Johnson Medical School (X.Y., A.T.T, Y.L., D.R.C.), Rutgers Translational Sciences, Department of Chemistry and Chemical Biology (S.D.K.), Department of Medicinal Chemistry, Rutgers Ernest Mario School of Pharmacy (J.G., A.F.B., S.D.K.), Rutgers University, New Brunswick, New Jersey; Department of Biochemistry and Molecular Biology, State University of New York (SUNY) Upstate Medical University, Syracuse, New York (A.B., S.N.L.); and Mount Sinai St. Luke's Roosevelt General Surgery Residency Program, New York, New York (A.T.T.).
Yue LiuRutgers Cancer Institute of New Jersey (X.Y., A.T.T., S.Z., Y.L., D.R.C.), Department of Surgery, Rutgers Robert Wood Johnson Medical School (X.Y., A.T.T, Y.L., D.R.C.), Rutgers Translational Sciences, Department of Chemistry and Chemical Biology (S.D.K.), Department of Medicinal Chemistry, Rutgers Ernest Mario School of Pharmacy (J.G., A.F.B., S.D.K.), Rutgers University, New Brunswick, New Jersey; Department of Biochemistry and Molecular Biology, State University of New York (SUNY) Upstate Medical University, Syracuse, New York (A.B., S.N.L.); and Mount Sinai St. Luke's Roosevelt General Surgery Residency Program, New York, New York (A.T.T.).
John GilleranRutgers Cancer Institute of New Jersey (X.Y., A.T.T., S.Z., Y.L., D.R.C.), Department of Surgery, Rutgers Robert Wood Johnson Medical School (X.Y., A.T.T, Y.L., D.R.C.), Rutgers Translational Sciences, Department of Chemistry and Chemical Biology (S.D.K.), Department of Medicinal Chemistry, Rutgers Ernest Mario School of Pharmacy (J.G., A.F.B., S.D.K.), Rutgers University, New Brunswick, New Jersey; Department of Biochemistry and Molecular Biology, State University of New York (SUNY) Upstate Medical University, Syracuse, New York (A.B., S.N.L.); and Mount Sinai St. Luke's Roosevelt General Surgery Residency Program, New York, New York (A.T.T.).
Anthony F BencivengaRutgers Cancer Institute of New Jersey (X.Y., A.T.T., S.Z., Y.L., D.R.C.), Department of Surgery, Rutgers Robert Wood Johnson Medical School (X.Y., A.T.T, Y.L., D.R.C.), Rutgers Translational Sciences, Department of Chemistry and Chemical Biology (S.D.K.), Department of Medicinal Chemistry, Rutgers Ernest Mario School of Pharmacy (J.G., A.F.B., S.D.K.), Rutgers University, New Brunswick, New Jersey; Department of Biochemistry and Molecular Biology, State University of New York (SUNY) Upstate Medical University, Syracuse, New York (A.B., S.N.L.); and Mount Sinai St. Luke's Roosevelt General Surgery Residency Program, New York, New York (A.T.T.).
S David KimballRutgers Cancer Institute of New Jersey (X.Y., A.T.T., S.Z., Y.L., D.R.C.), Department of Surgery, Rutgers Robert Wood Johnson Medical School (X.Y., A.T.T, Y.L., D.R.C.), Rutgers Translational Sciences, Department of Chemistry and Chemical Biology (S.D.K.), Department of Medicinal Chemistry, Rutgers Ernest Mario School of Pharmacy (J.G., A.F.B., S.D.K.), Rutgers University, New Brunswick, New Jersey; Department of Biochemistry and Molecular Biology, State University of New York (SUNY) Upstate Medical University, Syracuse, New York (A.B., S.N.L.); and Mount Sinai St. Luke's Roosevelt General Surgery Residency Program, New York, New York (A.T.T.).
Stewart N LohRutgers Cancer Institute of New Jersey (X.Y., A.T.T., S.Z., Y.L., D.R.C.), Department of Surgery, Rutgers Robert Wood Johnson Medical School (X.Y., A.T.T, Y.L., D.R.C.), Rutgers Translational Sciences, Department of Chemistry and Chemical Biology (S.D.K.), Department of Medicinal Chemistry, Rutgers Ernest Mario School of Pharmacy (J.G., A.F.B., S.D.K.), Rutgers University, New Brunswick, New Jersey; Department of Biochemistry and Molecular Biology, State University of New York (SUNY) Upstate Medical University, Syracuse, New York (A.B., S.N.L.); and Mount Sinai St. Luke's Roosevelt General Surgery Residency Program, New York, New York (A.T.T.) carpizdr@cinj.rutgers.edu lohs@upstate.edu.
Darren R CarpizoRutgers Cancer Institute of New Jersey (X.Y., A.T.T., S.Z., Y.L., D.R.C.), Department of Surgery, Rutgers Robert Wood Johnson Medical School (X.Y., A.T.T, Y.L., D.R.C.), Rutgers Translational Sciences, Department of Chemistry and Chemical Biology (S.D.K.), Department of Medicinal Chemistry, Rutgers Ernest Mario School of Pharmacy (J.G., A.F.B., S.D.K.), Rutgers University, New Brunswick, New Jersey; Department of Biochemistry and Molecular Biology, State University of New York (SUNY) Upstate Medical University, Syracuse, New York (A.B., S.N.L.); and Mount Sinai St. Luke's Roosevelt General Surgery Residency Program, New York, New York (A.T.T.) carpizdr@cinj.rutgers.edu lohs@upstate.edu.
Rutgers, The State University of New Jersey · USSt. Luke's-Roosevelt Hospital Center · USSUNY Upstate Medical University · US
Funding
Development of Zinc Metallochaperones as Mutant p53 Targeted Anti-cancerDrugsR01CA200800 · NCI · UNIVERSITY OF ROCHESTER · PI CARPIZO, DARREN RICHARD · 2016 to 2020
$1.9MExploration of a Mutant p53 Reactivating CompoundK08CA172676 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI CARPIZO, DARREN RICHARD · 2013 to 2017
$745kRestoring the Missing Zinc: A quantitative investigation of p53 hotspot mutant reactivation by synthetic metallochaperones for cancer chemotherapyF30GM113299 · NIGMS · UPSTATE MEDICAL UNIVERSITY · PI BLANDEN, ADAM · 2015 to 2016
$65kNCI NIH HHS K08 CA172676NCI NIH HHS R01 CA200800NIGMS NIH HHS F30 GM113299
Abstract
Small-molecule restoration of wild-type structure and function to mutant p53 (so-called mutant reactivation) is a highly sought-after goal in cancer drug development. We previously discovered that small-molecule zinc chelators called
Indexed as
Cell Line, TumorCell ProliferationDose-Response Relationship, DrugGrowth InhibitorsHumansMetallochaperonesMutationThiosemicarbazonesTumor Suppressor Protein p53ZincGrowth InhibitorsMetallochaperonesThiosemicarbazonesTumor Suppressor Protein p53Zinc
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.